Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Axitinib plus Gemcitabine in Advanced Pancreatic Cancer
NCT00471146Phase 3Completed
- Sponsor
- Pfizer
- Start
- Jul 2007
- Primary completion
- Jan 2009
- Modality
- Small Molecules
- Countries
- 24
01
Overview
Phase 3, randomised, double-blind trial in pancreatic ductal adenocarcinoma (PDAC) comparing Gemcitabine + Axitinib with Gemcitabine + Placebo (2 arms). Primary endpoint: Overall Survival. Started Jul 2007; status: completed.
02
Drugs
axitinib
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT00471146.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00471146.